| __timestamp | Apellis Pharmaceuticals, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 35942000 |
| Thursday, January 1, 2015 | 6356782 | 40028000 |
| Friday, January 1, 2016 | 4303743 | 45853000 |
| Sunday, January 1, 2017 | 10463151 | 53816000 |
| Monday, January 1, 2018 | 22639184 | 60804000 |
| Tuesday, January 1, 2019 | 67046483 | 77252000 |
| Wednesday, January 1, 2020 | 139401000 | 45736000 |
| Friday, January 1, 2021 | 176771000 | 50323000 |
| Saturday, January 1, 2022 | 277163000 | 143526000 |
| Sunday, January 1, 2023 | 500815000 | 149182000 |
| Monday, January 1, 2024 | 154335000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc. have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Apellis's SG&A expenses skyrocketed by over 17,000%, peaking in 2023. In contrast, Halozyme's expenses grew by approximately 315% during the same period. This divergence highlights Apellis's aggressive expansion strategy compared to Halozyme's more measured approach. Notably, in 2020, Apellis's SG&A expenses surpassed Halozyme's, marking a pivotal shift. By 2023, Apellis's spending was more than three times that of Halozyme, reflecting its commitment to scaling operations. These trends offer a window into each company's strategic priorities and market positioning, providing valuable insights for investors and industry analysts alike.
Comparing SG&A Expenses: AstraZeneca PLC vs Halozyme Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Incyte Corporation or Halozyme Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Summit Therapeutics Inc. and Halozyme Therapeutics, Inc.
Comparing SG&A Expenses: Walgreens Boots Alliance, Inc. vs Halozyme Therapeutics, Inc. Trends and Insights
Halozyme Therapeutics, Inc. or Amneal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. vs Mesoblast Limited: SG&A Expense Trends
Breaking Down SG&A Expenses: Pharming Group N.V. vs Apellis Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Apellis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Perrigo Company plc
SG&A Efficiency Analysis: Comparing Apellis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.